



Rockford Board of Education  
501 Seventh Street  
Rockford, IL 61104

August 18, 2015

## **Addendum No. 2: 16-09 RFP Pharmacy Benefits Manager**

---

To All Bidders:

Attached are modification, clarifications and/or corrections for the Project Manual and is hereby made a part of the contract documents. Please see attached to this addendum the Project Manual(s) in your possession. Please note the receipt of this addendum on the bid form. Bidders shall review changes to all portions of this work as changes to one portion may affect the work of another.

RFP Opening: **Friday, August 21, 2015 at 11:00 AM (CDST), Rockford Board of Education, 6<sup>th</sup> floor Conference Room, 501 Seventh St., Rockford, IL 61104.** The date and time as stated is also the time of the public opening. All vendors are welcome to attend the RFP opening.

**Copy of claims detail will be provided in an excel format in a separate document.**

Refer all questions relative to the business aspect, Instructions to Bidders, Special Conditions, and questions concerning the technical aspect of the documents to the Executive Director of Budget and Purchasing by email at [stacie.scott@rps205.com](mailto:stacie.scott@rps205.com).

ROCKFORD BOARD OF EDUCATION

By: Tamara Pugh

Purchasing Process Manager



# 1Q15 Plan Performance

Rockford Public Schools


05/21/15




# Rockford Public Schools' Compound Utilization

- In Q1'15, compounds made up 0.1% of Total Plan Cost, a decrease of 0.7 points over 0.8% in Q2'14
- PMPM trend excluding compounds was 12.0% versus overall trend of 10.0% between 1-14 - 3-14 and 1-15 - 3-15


Total Plan Cost and Total Rx's by Quarter



Plan Cost



# Key Metrics by Quarter



Generic Fill Rate % calculated with Unadjusted Rx's



# Plan Performance

- Total Plan Cost is \$1,659,465, an increase of 9.6% over the previous period
- Total Gross Cost is \$2,010,703, an increase of 7.0% over the previous period
- Total Member Cost is \$335,321, an increase of 0.1% over the previous period

Plan Performance			
	1-15 - 3-15	1-14 - 3-14	Change %
AWP	\$3,649,271	\$3,354,962	8.8%
Network & Mail Discount Savings (includes dispensing fees)	-\$1,655,498	-\$1,491,131	11.0%
Tax	\$16,930	\$15,788	7.2%
Gross Cost	\$2,010,703	\$1,879,619	7.0%
Member Cost	-\$335,321	-\$335,094	0.1%
Plan Cost*	\$1,659,465	\$1,514,325	9.6%
Members	7,715	7,747	-0.4%
Plan Cost PMPM	\$71.70	\$65.15	10.1%

\* Financial results have not been audited. Plan Costs do not include rebates.



# Top Line Performance Metrics

- Plan Cost PMPM is \$71.70, a 10.0% trend over the previous period
- Generic Fill Rate (GFR) increased 2.5 percentage points to 84.1%
- Specialty Plan Cost PMPM is \$18.75, a 26.3% trend over the previous period

Rockford Public Schools			
Description	1-15 - 3-15	1-14 - 3-14	Change
Avg Subscribers per Month	3,231	3,280	-1.5%
Avg Members per Month	7,715	7,747	-0.4%
Number of Unique Patients	3,802	3,749	1.4%
Pct Members Utilizing Benefit	49.3%	48.4%	0.9
Total Plan Cost	\$1,659,465	\$1,514,325	9.6%
Total Days	601,019	571,396	5.2%
Total Rxs	15,053	14,595	3.1%
Average Member Age	33.9	33.8	0.1%
Plan Cost PMPM	\$71.70	\$65.15	10.0%
Plan Cost/Day	\$2.76	\$2.65	4.2%
Plan Cost per Rx	\$110.24	\$103.76	6.3%
Nbr Rxs PMPM	0.65	0.63	3.6%
Generic Fill Rate	84.1%	81.6%	2.5
Home Delivery Utilization	58.9%	58.1%	0.8
Member Cost %	16.7%	17.8%	-1.2
Specialty Percent of Plan Cost	26.2%	22.8%	3.4
Specialty Plan Cost PMPM	\$18.75	\$14.85	26.3%
Formulary Compliance Rate	97.6%	97.0%	0.6

Midmarket Employer - Elementary & Secondary Schools		Book of Business	
1-15 - 3-15	Change	1-15 - 3-15	Change
36.7		39.6	
\$109.87	8.9%	\$92.61	11.0%
\$3.15	6.3%	\$2.53	7.6%
\$115.84	5.6%	\$93.68	7.5%
0.95	3.2%	0.99	3.3%
81.7%	2.0	83.9%	1.6
36.8%	-1.7	33.9%	-0.9
11.4%	-1.0	14.8%	-1.1
25.6%	0.9	27.2%	2.2
\$28.10	12.7%	\$25.21	20.7%
95.5%	0.6	95.4%	0.6



# Top Line Performance: Specialty

- Plan Cost PMPM trend on specialty drugs is 26.3%, compared to a 5.2% Plan Cost PMPM trend on non-specialty drugs
- There are 43 unique specialty patients, a decrease of 4 specialty patients over the previous period

Rockford Public Schools						
Description	Non-Specialty			Specialty		
	1-15 - 3-15	1-14 - 3-14	Change	1-15 - 3-15	1-14 - 3-14	Change
Avg Subscribers per Month	3,231	3,280	-1.5%	3,231	3,280	-1.5%
Avg Members per Month	7,715	7,747	-0.4%	7,715	7,747	-0.4%
Number of Unique Patients	3,799	3,741	1.6%	43	47	-8.5%
Pct Members Utilizing Benefit	49.2%	48.3%	1.0	0.6%	0.6%	0.0
Total Plan Cost	\$1,225,370	\$1,169,144	4.8%	\$434,095	\$345,180	25.8%
Percent of Total Plan Cost	73.8%	77.2%	-3.4	26.2%	22.8%	3.4
Total Days	598,091	568,071	5.3%	2,928	3,325	-11.9%
Total Rxs	14,983	14,513	3.2%	70	82	-14.6%
Percent of Total Rxs	99.53%	99.44%	0.1	0.47%	0.56%	-0.1
Plan Cost PMPM	\$52.94	\$50.30	5.2%	\$18.75	\$14.85	26.3%
Plan Cost/Day	\$2.05	\$2.06	-0.5%	\$148.26	\$103.81	42.8%
Plan Cost per Rx	\$81.78	\$80.56	1.5%	\$6,201.36	\$4,209.52	47.3%
Nbr Rxs PMPM	0.65	0.62	3.7%	0.003	0.004	-14.3%
Generic Fill Rate	84.4%	82.0%	2.4	12.9%	18.3%	-5.4
Member Cost %	21.1%	21.7%	-0.6	1.0%	1.3%	-0.4

Specialty Midmarket Employer - Elementary & Secondary Schools	
1-15 - 3-15	Change
\$28.10	12.7%
\$160.80	19.3%
\$5,584.09	15.2%
0.005	-2.1%
16.5%	2.5
1.8%	0.3

# Clinical Savings and Impact

- Rockford Public Schools saved \$180,119 by helping patients make clinically appropriate decisions via Clinical Programs
- Savings from these programs decreased Plan Cost PMPM by 9.8%

Plan Cost Savings			
Program	Current 1-15 - 3-15	Previous 1-14 - 3-14	Change
AUM	\$25,414	\$11,764	116.0%
CDUR	\$153,692	\$103,350	48.7%
RDUR	\$0	\$0	0.0%
RationalMED	\$0	\$0	0.0%
Interchange	\$1,014	\$2,689	-62.3%


AUM - Advanced Utilization Management

CDUR - Concurrent Drug Utilization Review (health and safety edits)

RDUR - Retrospective Drug Utilization Review

RationalMED - Clinical Outreach Program that includes messaging to physicians, pharmacists, and members (optional) regarding health and safety issues.

Interchange - Consists of two primary programs the first targets Multi-Source Brand drugs with DAW 1 or 3 alerting patients or prescribers of a Generic equivalent. The second program targets non-preferred Single-Source Brand drugs alerting prescribers of a therapeutically equivalent lower cost Generic alternative or Preferred Brand.



Program fees are not included in these savings numbers.





# Trend Components

- Non-specialty Plan Cost PMPM trend is 5.2% while specialty is at 26.3%
- Inflation is the largest cost driver of your non-specialty Plan Cost PMPM
- Drug Mix is the largest cost saver of your non-specialty Plan Cost PMPM

	OVERALL	NON- SPECIALTY	SPECIALTY
Previous Plan Cost PMPM	\$65.15	\$50.30	\$14.85
Utilization	↑ 6.0%	↑ 5.8%	↓ -16.1%
Inflation	↑ 8.4%	↑ 7.7%	↑ 15.4%
Drug Mix	↓ -4.5%	↓ -6.2%	↑ 27.3%
Discount	↓ -1.5%	↓ -3.1%	↓ -1.1%
Cost Share	↑ 1.7%	↑ 1.0%	↑ 0.8%
Change in Plan Cost PMPM	10.0%	5.2%	26.3%
Current Plan Cost PMPM	\$71.70	\$52.94	\$18.75

Date Range 1-15 - 3-15 versus 1-14 - 3-14

Utilization based on change in days PMPM

Inflation based on change in AWP/quantity at a drug level

Drug Mix based on changes in therapy, addition of new therapies and the blend of brand/generics




Discount based on change in aggregate AWP discount

Cost share based on change in aggregate member share




# Trend Components: Utilization

- Prevalence (patients per member) has increased 0.9 points
- Intensity (days per patient) has increased 3.7%



# Trend Components: Inflation

- Brand Drug inflation accounted for an increase of \$5.45 in Plan Cost PMPM
- Reduce this impact by moving members away from highly inflated brands to generic therapeutic alternatives




## Brand Drug Inflation - Top Impacted Drugs\*

Drug Name/ Strength	Specialty Flag	Scheduled Release	1-15 - 3-15			1-14 - 3-14			% Change	
			AWP	QTY	AWP/QTY	AWP	QTY	AWP/QTY	AWP/QTY	Inflation Impact on AWP
MYSOLINE 250 MG	No	N/A	\$24,171	540	\$44.76	\$6,976	540	\$12.92	246.5%	\$17,195
HUMIRA 40MG/0.8ML	Yes	2016	\$115,380	66	\$1,748.19	\$108,113	72	\$1,501.57	16.4%	\$16,277
HUMALOG 100/ML	No	N/A	\$45,887	1,600	\$28.68	\$48,686	2,120	\$22.97	24.9%	\$9,143
WELLBUTRIN XL 300 MG	No	N/A	\$13,190	360	\$36.64	\$3,113	180	\$17.29	111.9%	\$6,964
ENBREL 50 MG/ML	Yes	N/A	\$45,461	51	\$892.09	\$36,381	47	\$773.41	15.3%	\$6,048
LANTUS SOLOSTAR 100/ML (3)	No	N/A	\$31,759	1,065	\$29.82	\$23,279	960	\$24.25	23.0%	\$5,933
CLOBETASOL PROPIONATE 0.0005	No	N/A	\$7,765	1,050	\$7.40	\$1,699	965	\$1.76	319.9%	\$5,916
TREXIMET 85MG-500MG	No	N/A	\$9,007	108	\$83.40	\$4,129	126	\$32.77	154.5%	\$5,468
ANUCORT-HC 25 MG	No	N/A	\$5,594	260	\$21.51	\$1,184	200	\$5.92	263.5%	\$4,055
LANTUS 100/ML	No	N/A	\$17,594	590	\$29.82	\$19,488	849	\$22.95	29.9%	\$4,052

\*Compounds are excluded from the Top 10 Impacted Drugs

# Trend Components: Specialty Inflation


- Brand Drug inflation accounted for an increase of \$2.29 in Specialty Plan Cost PMPM
- Reduce this impact by moving members away from highly inflated brands to generic therapeutic alternatives



Brand Drug Inflation - Top Impacted Drugs										
Drug Name/ Strength	Specialty Flag	Scheduled Release	1-15 - 3-15			1-14 - 3-14			% Change	
			AWP	QTY	AWP/ QTY	AWP	QTY	AWP/ QTY	AWP/ QTY	Inflation Impact on AWP
HUMIRA 40MG/0.8ML	Yes	2016	\$115,380	66	\$1,748.19	\$108,113	72	\$1,501.57	16.4%	\$16,277
ENBREL 50 MG/ML	Yes	N/A	\$45,461	51	\$892.09	\$36,381	47	\$773.41	15.3%	\$6,048
REBIF 44MCG/.5ML	Yes	2026	\$19,561	18	\$1,086.74	\$34,822	36	\$967.28	12.4%	\$2,150
GONAL-F RFF REDI-JECT 300/0.5ML	Yes	N/A	\$19,230	15	\$1,326.24	\$4,835	4	\$1,208.64	9.7%	\$1,705
FORTEO 20MCG/DOSE	Yes	2019	\$6,330	7	\$879.10	\$5,103	7	\$708.70	24.0%	\$1,227
MENOPUR 75 UNIT	Yes	N/A	\$6,976	42	\$166.10	\$7,275	53	\$137.27	21.0%	\$1,211
PULMOZYME 1 MG/ML	Yes	N/A	\$10,135	225	\$45.04	\$9,298	225	\$41.32	9.0%	\$837
GONAL-F RFF REDI-JECT 900/1.5 ML	Yes	N/A	\$3,979	3	\$1,326.24	\$13,755	12	\$1,146.24	15.7%	\$540
XOLAIR 150 MG	Yes	N/A	\$6,051	6	\$1,008.49	\$13,054	14	\$932.41	8.2%	\$456
AMPYRA 10 MG	Yes	N/A	\$4,264	120	\$35.54	\$7,687	240	\$32.03	10.9%	\$421

# Trend Components: Member Cost

- Overall Member Cost is 16.7% a 1.2 point decrease over previous period



**Previous Member Cost %**      **Current Member Cost %**











## Clinical Review



# A TRC-Stratified Look at Your Member Population



 Rare and Specialty	 Oncology	 HIV/ Immunology	 Diabetes	 Cardio-vascular	 Pulmonary	 Neuro-science	 Women's Health
<b>PATIENTS</b>							
47	32	55	329	690	726	1,047	271
<b>PLAN COST SPEND</b>							
\$0.4M	\$67.8K	\$85.6K	\$0.3M	\$0.2M	\$0.2M	\$0.3M	\$38.0K
<b>PLAN COST % SPEND</b>							
23.7%	4.1%	5.2%	15.3%	14.5%	10.3%	18.1%	2.3%

Clinical specialization in a specific condition helps to **better identify issues and improve health outcomes.**

Specialist pharmacists learn **extensive communication skills to enhance the patient experience and improve adherence.**

MEMBER SATISFACTION AT  
**98%\***  
FOR SPECIALIST PHARMACISTS

Reporting period: January 01, 2015 thru March 31, 2015. Spend based on Plan Cost.

\* Member Satisfaction rates are not client specific.



# Patient Stratification

## Patient Care Needs

### Well

Smoking Cessation, Allergies, Constipation/Anti diarrheals, Topical Antifungal / Anti-bacterial infection treatment

### Acute

Colds & Flu, Strep Throat, Ear Infection, Headache, Sprains


### Chronic

Heart Disease, Diabetes, Arthritis, High Blood Pressure, High Cholesterol, Dementia, Back Pain


### Complex

Multiple Chronic Conditions such as Heart Failure & Diabetes, Cancer, AIDS, Multiple Sclerosis, Metabolic Syndrome

### Current



### Previous



	Well	Acute	Chronic	Complex	Total
Members	4,095	629	2,494	497	<b>7,715</b>
Members %	53.1%	8.2%	32.3%	6.4%	<b>100.0%</b>
Plan Cost	\$37,591	\$68,538	\$828,013	\$725,322	<b>\$1,659,465</b>
Plan Cost %	2.3%	4.1%	49.9%	43.7%	<b>100.0%</b>
Member Age (Avg.)	26.4	25.1	42.2	49.8	<b>33.9</b>
Copay	\$4,214	\$18,487	\$215,466	\$97,153	<b>\$335,321</b>
Copay/Member	\$1	\$29	\$86	\$195	<b>\$43</b>
Plan Spend/Member	\$9	\$109	\$332	\$1,459	<b>\$215</b>
Days of Therapy/Member	2.6	34.7	154.2	369.7	<b>77.9</b>
GFR %	78.7%	89.4%	84.1%	82.8%	<b>84.1%</b>
Home Delivery Utilization	45.4%	25.9%	58.7%	64.0%	<b>58.9%</b>

GFR % calculated with Unadjusted Rxs



# Top 10 Indications

- The largest trend is in Multiple Sclerosis, at 98.3%

**REPRESENT**  
**57.4%**  
**OF YOUR TOTAL**  
**PLAN COST**

Top Indications by Plan Cost															
1-15 - 3-15										1-14 - 3-14					%
AUM Mgmt. Strategy	Rank	Peer Rank	Indication	Rxs	Patients	Plan Cost	Peer			Rank	Rxs	Patients	Generic Fill Rate	Plan Cost PMPM	% Plan Cost
							Generic Fill Rate	Generic Fill Rate	Plan Cost PMPM						
ST/PA/DQM	1	1	DIABETES	825	288	\$170,671	47.9%	44.1%	\$7.37	2	673	271	47.3%	\$5.74	28.4%
ST/PA/DQM	2	2	INFLAMMATORY CONDITIONS	49	32	\$165,510	26.5%	21.9%	\$7.15	1	59	38	28.8%	\$6.56	9.0%
ST/PA/DQM	3	4	MULTIPLE SCLEROSIS	13	9	\$134,913	0.0%	0.0%	\$5.83	6	6	6	0.0%	\$2.94	98.3%
ST/PA	4	12	ATTENTION DISORDERS	622	258	\$107,010	68.3%	71.3%	\$4.62	3	596	248	64.6%	\$3.92	17.8%
ST/DQM	5	16	DEPRESSION	1,208	658	\$80,075	94.4%	95.2%	\$3.46	4	1,108	617	94.3%	\$3.52	-1.6%
ST/PA/DQM	6	3	HIGH BLOOD CHOLESTEROL	724	501	\$74,053	82.2%	80.7%	\$3.20	7	737	502	81.3%	\$2.70	18.5%
ST/PA/DQM	7	13	MENTAL/NEURO DISORDERS	189	93	\$60,147	75.1%	63.0%	\$2.60	8	169	82	70.4%	\$2.54	2.2%
ST/PA/DQM	8	7	ASTHMA	552	367	\$59,096	40.8%	41.7%	\$2.55	9	505	339	35.6%	\$2.23	14.6%
ST/DQM	9	17	CONTRACEPTIVES	850	455	\$51,767	82.9%	76.5%	\$2.24	14	805	445	80.7%	\$1.93	16.1%
ST/PA/DQM	10	5	PAIN/INFLAMMATION	1,328	686	\$49,268	95.9%	93.0%	\$2.13	10	1,397	730	92.6%	\$2.21	-3.8%
<b>Total Top 10:</b>				<b>6,360</b>		<b>\$952,511</b>	<b>77.2%</b>		<b>\$41.15</b>		<b>6,055</b>		<b>76.1%</b>	<b>\$34.29</b>	<b>20.0%</b>
<b>Differences Between Periods:</b>				<b>305</b>		<b>\$155,442</b>	<b>1.2%</b>		<b>\$6.86</b>						

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment



# Top 25 Drugs

- Represent 43.8% of your total Plan Cost and comprise 16 indications
- 9 of your top 25 are specialty drugs

Top Drugs by Plan Cost														
AUM Mgmt. Strategy	Rank		Peer Rank		Brand Name		Indication		1-15 - 3-15		1-14 - 3-14			% Change
									Rxs	Pts.	Plan Cost	Plan Cost / PMPM	Rank	
ST/PA/DQM	1	2	HUMIRA		INFLAMMATORY CONDITIONS	11	10	\$98,526	\$4.26	1	13	12	\$4.07	4.5%
ST/PA	2	9	COPAXONE		MULTIPLE SCLEROSIS	8	5	\$82,295	\$3.56	7	2	2	\$1.34	164.6%
PA	3	227	XALKORI		CANCER	3	1	\$40,468	\$1.75					
ST/PA/DQM	4	3	ENBREL		INFLAMMATORY CONDITIONS	4	3	\$38,847	\$1.68	8	4	4	\$1.33	25.7%
DQM	5	7	ABILIFY		MENTAL/NEURO DISORDERS	29	20	\$38,462	\$1.66	4	42	24	\$1.61	3.4%
DQM	6	14	DULOXETINE HCL		DEPRESSION	117	76	\$35,874	\$1.55	2	126	76	\$2.46	-37.0%
N/A	7	8	HUMALOG		DIABETES	36	29	\$33,515	\$1.45	5	51	37	\$1.50	-3.5%
ST	8	5	HARVONI		HEPATITIS	1	1	\$32,446	\$1.40					
ST/DQM	9	4	CRESTOR		HIGH BLOOD CHOLESTEROL	68	58	\$25,562	\$1.10	14	73	55	\$0.95	15.7%
ST/PA	10	17	VYVANSE		ATTENTION DISORDERS	119	55	\$23,438	\$1.01	16	102	49	\$0.80	26.8%
N/A	11	10	LANTUS SOLOSTAR		DIABETES	33	28	\$23,058	\$1.00	21	31	26	\$0.71	40.9%
PA	12	20	DEXTRAMPHETAMINE-AMPHET ER		ATTENTION DISORDERS	144	65	\$23,006	\$0.99	13	145	59	\$0.96	3.6%
ST/DQM	13	6	NEXIUM		HEARTBURN/ULCER DISEASE	41	34	\$20,996	\$0.91	3	73	65	\$1.71	-47.0%
ST	14	51	SOLODYN		INFECTIOUS	18	11	\$20,116	\$0.87	6	30	15	\$1.35	-35.6%
N/A	15	42	GONAL-F RFF REDI-JECT		INFERTILITY	9	5	\$19,904	\$0.86	22	4	3	\$0.69	25.0%
N/A	16	780	MYSOLINE		SEIZURES	1	1	\$18,548	\$0.80	66	1	1	\$0.23	253.6%
PA	17	27	METHYLPHENIDATE ER		ATTENTION DISORDERS	100	51	\$18,102	\$0.78	20	110	52	\$0.76	2.5%
DQM	18	82	ESOMEPRAZOLE MAGNESIUM		HEARTBURN/ULCER DISEASE	28	28	\$18,034	\$0.78					
ST/DQM	19	12	JANUVIA		DIABETES	37	23	\$17,652	\$0.76	31	22	17	\$0.44	71.4%
ST/PA/DQM	20	49	REBIF		MULTIPLE SCLEROSIS	1	1	\$17,168	\$0.74	9	2	2	\$1.31	-43.6%
ST/PA	21	140	REBIF REBIDOSE		MULTIPLE SCLEROSIS	1	1	\$17,168	\$0.74					
ST/PA	22	47	STELARA		SKIN CONDITIONS	1	1	\$16,132	\$0.70					
PA/DQM	23	15	SYMBICORT		ASTHMA	45	32	\$15,741	\$0.68	24	48	38	\$0.64	7.0%
PA/DQM	24	28	VIAGRA		IMPOTENCE	40	33	\$15,517	\$0.67	26	33	29	\$0.57	17.1%
PA/DQM	25	35	CIALIS		IMPOTENCE	31	27	\$15,447	\$0.67	10	54	40	\$1.21	-44.9%
					Total Top 25:	926		\$726,023	\$31.37		966		\$24.66	27.2%
					Differences Between Periods:	-40		\$152,981	\$6.71					

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment

# Top Specialty Indications

- Less than 1% of your claims account for 26.2% of your Plan Cost
- The largest trend is in Multiple Sclerosis, at 98.3%

Top Specialty Indications by Plan Cost														
1-15 - 3-15								1-14 - 3-14					%	
AUM Mgmt. Strategy	Overall Rank	Overall Peer Rank	Indication	Rxs	Patients	Plan Cost	PMPM	Overall Rank	Rxs	Patients	Plan Cost	PMPM	Plan Cost	Plan Cost PMPM
ST/PA/DQM	2	2	INFLAMMATORY CONDITIONS	16	14	\$145,222	\$6.27	1	18	17	\$133,645	\$5.75		9.1%
ST/PA/DQM	3	4	MULTIPLE SCLEROSIS	13	9	\$134,913	\$5.83	6	6	6	\$68,322	\$2.94		98.3%
PA	13	6	CANCER	4	2	\$40,717	\$1.76	11	10	6	\$46,452	\$2.00		-12.0%
ST	19	9	HEPATITIS	1	1	\$32,446	\$1.40							
DQM	21	31	INFERTILITY	21	5	\$28,333	\$1.22	20	26	8	\$28,126	\$1.21		1.2%
ST/PA	12	14	SKIN CONDITIONS	1	1	\$16,132	\$0.70	18						
N/A	33	38	RESPIRATORY CONDITIONS	1	1	\$8,856	\$0.38	31	1	1	\$8,119	\$0.35		9.5%
ST/PA/DQM	10	5	PAIN/INFLAMMATION	2	1	\$7,776	\$0.34	10						
ST/PA/DQM	39	45	BONE CONDITIONS	1	1	\$5,319	\$0.23	39	1	1	\$4,316	\$0.19		23.7%
PA/DQM	31	33	ENDOCRINE DISORDERS	1	1	\$5,148	\$0.22	26	3	3	\$8,869	\$0.38		-41.7%
<b>Total Top 10:</b>				<b>61</b>		<b>\$424,864</b>	<b>\$18.36</b>		<b>65</b>		<b>\$297,848</b>	<b>\$12.82</b>		<b>43.2%</b>
<b>Differences Between Periods:</b>				<b>-4</b>		<b>\$127,015</b>	<b>\$5.54</b>							

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment



# Top 24 Specialty Drugs

- Represent 26.2% of your total Plan Cost and comprise 13 indications

## Top Specialty Drugs by Plan Cost

		1-15 - 3-15								1-14 - 3-14					% Change
AUM Mgmt. Strategy	Overall Rank	Overall Peer Rank	Brand Name	Indication	Rxs	Pts.	Plan Cost	Plan Cost / Rx	Plan Cost PMPM	Overall Rank	Rxs	Pts.	Plan Cost / Rx	Plan Cost PMPM	Plan Cost PMPM
ST/PA/DQM	1	2	HUMIRA	INFLAMMATORY CONDITIONS	11	10	\$98,526	\$8,957	\$4.26	1	13	12	\$7,284	\$4.07	4.5%
ST/PA	2	9	COPAXONE	MULTIPLE SCLEROSIS	8	5	\$82,295	\$10,287	\$3.56	7	2	2	\$15,615	\$1.34	164.6%
PA	3	227	XALKORI	CANCER	3	1	\$40,468	\$13,489	\$1.75						
ST/PA/DQM	4	3	ENBREL	INFLAMMATORY CONDITIONS	4	3	\$38,847	\$9,712	\$1.68	8	4	4	\$7,756	\$1.33	25.7%
ST	8	5	HARVONI	HEPATITIS	1	1	\$32,446	\$32,446	\$1.40						
N/A	15	42	GONAL-F RFF REDI-JECT	INFERTILITY	9	5	\$19,904	\$2,212	\$0.86	22	4	3	\$3,998	\$0.69	25.0%
ST/PA/DQM	20	49	REBIF	MULTIPLE SCLEROSIS	1	1	\$17,168	\$17,168	\$0.74	9	2	2	\$15,272	\$1.31	-43.6%
ST/PA	21	140	REBIF REBIDOSE	MULTIPLE SCLEROSIS	1	1	\$17,168	\$17,168	\$0.74						
ST/PA	22	47	STELARA	SKIN CONDITIONS	1	1	\$16,132	\$16,132	\$0.70						
ST/PA/DQM	26	64	AVONEX PEN	MULTIPLE SCLEROSIS	1	1	\$14,721	\$14,721	\$0.64						
N/A	41	105	PULMOZYME	RESPIRATORY CONDITIONS	1	1	\$8,856	\$8,856	\$0.38	42	1	1	\$8,119	\$0.35	9.5%
ST	47	160	XELJANZ	INFLAMMATORY CONDITIONS	1	1	\$7,849	\$7,849	\$0.34						
ST/PA	48	188	OTEZLA	PAIN/INFLAMMATION	2	1	\$7,776	\$3,888	\$0.34						
N/A	62	107	MENOPUR	INFERTILITY	3	2	\$5,971	\$1,990	\$0.26	58	6	3	\$1,020	\$0.26	-2.1%
PA/DQM	70	126	FORTEO	BONE CONDITIONS	1	1	\$5,319	\$5,319	\$0.23	75	1	1	\$4,316	\$0.19	23.7%
PA	71	270	SENSIPAR	ENDOCRINE DISORDERS	1	1	\$5,148	\$5,148	\$0.22	57	2	2	\$3,114	\$0.27	-17.0%
PA/DQM	72	52	XOLAIR	ASTHMA	1	1	\$5,133	\$5,133	\$0.22	29	3	2	\$3,669	\$0.47	-53.2%
N/A	87	46	ENOXAPARIN SODIUM	ANTICOAGULANT	7	7	\$3,871	\$553	\$0.17	34	5	3	\$1,867	\$0.40	-58.4%
PA	92	163	AMPYRA	MULTIPLE SCLEROSIS	2	1	\$3,562	\$1,781	\$0.15	51	2	2	\$3,274	\$0.28	-45.4%
N/A	175	419	GANIRELIX ACETATE	INFERTILITY	2	2	\$1,800	\$900	\$0.08	248	3	2	\$284	\$0.04	112.0%
N/A	374	996	OVIDREL	INFERTILITY	6	4	\$432	\$72	\$0.02	307	5	4	\$111	\$0.02	-21.8%
PA	445	867	LEUPROLIDE ACETATE	CANCER	1	1	\$249	\$249	\$0.01	162	5	3	\$336	\$0.07	-85.1%
PA	461	445	BOTOX	NEUROMUSCULAR CONDITIONS/COSMET	1	1	\$227	\$227	\$0.01						
DQM	462	705	CHORIONIC GONADOTROPIN	INFERTILITY	1	1	\$226	\$226	\$0.01	340	2	2	\$227	\$0.02	-50.0%
				Total Top 24:	70		\$434,095	\$6,201	\$18.75		60		\$4,312	\$11.13	68.5%
				Difference Between Periods:	10		\$175,397	\$1,890	\$7.62						

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment




# Upcoming Patent Expirations

- Implement programs now to realize savings on brand drugs losing patent protection
- Based on your current utilization, \$415,673 in brand drugs are losing patent protection by 2019

Top Drugs Scheduled to Lose Patent Protection through 2019					
Drug Name	Indication	Scheduled Release Year	Plan Cost Rank	Plan Cost PMPM	Plan Cost / Rx
HUMIRA	INFLAMMATORY CONDITIONS	2016	1	\$4.26	\$8,956.89
ABILIFY	MENTAL/NEURO DISORDERS	2015	5	\$1.66	\$1,326.27
CRESTOR	HIGH BLOOD CHOLESTEROL	2016	9	\$1.10	\$375.92
NEXIUM	HEARTBURN/ULCER DISEASE	2015	13	\$0.91	\$512.09
COPAXONE	MULTIPLE SCLEROSIS	2015	2	\$0.82	\$18,871.97
ESOMEPRAZOLE MAGNESI	HEARTBURN/ULCER DISEASE	2015	18	\$0.78	\$644.09
VIAGRA	IMPOTENCE	2017	24	\$0.67	\$387.93
CIALIS	IMPOTENCE	2018	25	\$0.67	\$498.29
ZETIA	HIGH BLOOD CHOLESTEROL	2016	29	\$0.56	\$416.06
SOLODYN	INFECTIONS	2019	14	\$0.48	\$1,006.03

## Spend on Brand Drugs Losing Patent Protection



Expiration dates based on current status and may change due to litigation, patent challenges, etc.

For every **1%** increase in GFR the plan could save approximately **2.9%** of total plan cost

GFR Savings calculation excludes Specialty drugs

# Generic Fill Rate Opportunity

Every 1% increase in GFR leads to Plan Cost savings of

**2.9%**

Increased GFR this period saved you


**\$126,449**

Improve your GFR to maximum potential of

**91.2%**

Savings calculations exclude Specialty drugs  
GFR and Maximum Potential GFR calculated with Unadjusted Rx's


## Generic Fill Rate Potential



# Plan Demographics

- The average member age is 33.9 years old, an increase of 0 years over the previous time period
- The 65+ age group has the highest Plan Cost per member at \$522.68
- ACA's Dependent Care Coverage to Age 26 requirement has impacted the age group 20-29

## Generic Fill Rate by Age Group



Age Group	Members	% Change	Days	% Change	Plan Cost	% Change	Plan Cost/Member	% Change	Patient/Member	% Change	Days/Member	% Change
0-9	1,015	0.6%	15,135	11.4%	\$55,611	3.1%	\$54.79	2.5%	34.8%	0.1	14.91	10.7%
10-19	1,363	-2.4%	42,312	15.7%	\$154,312	7.1%	\$113.22	9.7%	36.0%	2.4	31.04	18.5%
20-29	1,134	2.6%	46,096	-1.7%	\$172,715	3.3%	\$152.35	0.6%	43.0%	1.4	40.66	-4.2%
30-39	989	-0.9%	60,717	4.4%	\$223,722	23.7%	\$226.29	24.8%	50.2%	1.7	61.41	5.3%
40-49	1,154	-1.8%	100,425	4.9%	\$293,800	6.7%	\$254.52	8.8%	54.8%	-0.4	87.00	6.9%
50-59	1,289	-1.7%	180,600	4.3%	\$431,916	2.1%	\$335.17	3.9%	62.4%	-0.1	140.14	6.1%
60-64	499	1.7%	88,404	2.6%	\$184,870	20.2%	\$370.23	18.2%	73.1%	-0.2	177.04	0.9%
65+	273	3.9%	67,330	10.2%	\$142,518	22.5%	\$522.68	17.8%	74.1%	-4.1	246.93	6.0%
<b>Total</b>	<b>7,715</b>	<b>-0.4%</b>	<b>601,019</b>	<b>5.2%</b>	<b>\$1,659,465</b>	<b>9.6%</b>	<b>\$215.09</b>	<b>10.0%</b>	<b>49.3%</b>	<b>0.9</b>	<b>77.90</b>	<b>5.6%</b>


Generic Fill Rate calculated with Unadjusted Rxs

# Non-Preferred Drug Costs

## \$0.2 Million In Plan Cost

- The top 25 Non-Formulary Brand drugs represent \$132,145 or 8.0% of the Plan Cost
- Rockford Public Schools spent \$0.2 million on Non-Formulary Brand drugs in the current period
- These drugs generally do not earn rebates and could be targeted to shift to generics or lower cost brands without adversely impacting rebates

Current Plan Cost



Drug Name	Drug Description	Qty	Rxs		Plan Cost	
				Change	Total	Change
1 HARVONI	HEPATITIS	1		0.0%	\$32,446	0.0%
2 MYSOLINE	SEIZURES	1		0.0%	\$18,548	252.1%
3 WELLBUTRIN XL	DEPRESSION	4		33.3%	\$9,708	228.5%
4 XELJANZ	INFLAMMATORY CONDITIONS	1		0.0%	\$7,849	0.0%
5 ORTHO TRI-CYCLEN LO	CONTRACEPTIVES	29		3.6%	\$6,397	16.2%
6 TOPAMAX	SEIZURES	2		0.0%	\$5,556	11.9%
7 AMRIX	MUSCLE RELAXANT	7		600.0%	\$5,099	710.4%
8 JUBLIA	SKIN INFECTIONS	11		0.0%	\$4,472	0.0%
9 ADVAIR DISKUS	ASTHMA	15		650.0%	\$4,061	754.8%
10 RETIN-A MICRO PUMP	ACNE	5		0.0%	\$3,943	0.0%
11 AMBIEN CR	SLEEP DISORDERS	5		-28.6%	\$3,842	29.7%
12 BRINTELLIX	DEPRESSION	12		500.0%	\$3,527	1527.1%
13 KEPPRA	SEIZURES	1		#DIV/O!	\$2,953	#DIV/O!
14 TROKENDI XR	SEIZURES	5		0.0%	\$2,868	0.0%
15 DORYX	INFECTIONS	3		200.0%	\$2,708	270.2%
16 DEXILANT	HEARTBURN/ULCER DISEASE	7		-22.2%	\$2,223	33.3%
17 CAMBIA	MIGRAINE HEADACHES	5		25.0%	\$2,164	121.6%
18 FOCALIN XR	ATTENTION DISORDERS	6		0.0%	\$1,990	119.6%
19 GENERESS FE	CONTRACEPTIVES	8		-46.7%	\$1,883	-5.4%
20 FETZIMA	DEPRESSION	10		233.3%	\$1,713	274.0%
21 OSPHENA	ENDOCRINE DISORDERS	7		0.0%	\$1,711	0.0%
22 PREVACID	HEARTBURN/ULCER DISEASE	3		-50.0%	\$1,707	-13.5%
23 PREMARIN	VAGINAL DISORDERS	7		75.0%	\$1,614	34.7%
24 FORTAMET	DIABETES	2		0.0%	\$1,589	0.0%
25 LIVALO	HIGH BLOOD CHOLESTEROL	5		-44.4%	\$1,574	27.1%







## Utilization and Clinical Drivers



# Top Trend Drivers: Increases

## By Indication

- Majority due to increased Utilization

Overall Trend	
Current Plan Cost PMPM	\$71.70
Previous Plan Cost PMPM	\$65.15
% Change Plan Cost PMPM	10.0%

Total Trend %	
---------------	--

Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (+)
1	MULTIPLE SCLEROSIS	3	\$5.83	\$2.94	98.3%	\$2.89	Utilization
2	DIABETES	1	\$7.37	\$5.74	28.4%	\$1.63	Utilization
3	HEPATITIS	19	\$1.40		0.0%	\$1.40	Newly Utilized
4	SEIZURES	11	\$2.10	\$1.03	103.3%	\$1.07	Discount
5	ATTENTION DISORDERS	4	\$4.62	\$3.92	17.8%	\$0.70	Inflation/ Mix
6	SKIN CONDITIONS	12	\$2.08	\$1.43	45.6%	\$0.65	Inflation/ Mix
7	INFLAMMATORY CONDITIONS	2	\$7.15	\$6.56	9.0%	\$0.59	Inflation/ Mix
8	HIGH BLOOD CHOLESTEROL	6	\$3.20	\$2.70	18.5%	\$0.50	Inflation/ Mix
9	ASTHMA	8	\$2.55	\$2.23	14.6%	\$0.33	Utilization
10	CONTRACEPTIVES	9	\$2.24	\$1.93	16.1%	\$0.31	Utilization



# Top Trend Drivers: Decreases

## By Indication

- Decreases in trend vary by drug class and may be due to a number of factors, including new generics, new dispensing guidelines or changes in benefit design

Overall Trend	
Current Plan Cost PMPM	\$71.70
Previous Plan Cost PMPM	\$65.15
% Change Plan Cost PMPM	10.0%

Total Trend %							
Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (-)
1	INFECTIONS	15	\$1.84	\$3.33	-44.7%	-\$1.49	Inflation/ Mix
2	SLEEP DISORDERS	24	\$0.83	\$1.97	-57.9%	-\$1.14	Discount
3	MISC CONDITIONS	51	\$0.07	\$1.18	-93.7%	-\$1.11	Inflation/ Mix
4	IMPOTENCE	20	\$1.34	\$1.79	-25.3%	-\$0.45	Utilization
5	ANTICOAGULANT	25	\$0.82	\$1.15	-28.3%	-\$0.33	Inflation/ Mix
6	ENDOCRINE DISORDERS	31	\$0.39	\$0.65	-40.9%	-\$0.27	Inflation/ Mix
7	HORMONAL SUPPLEMENTATION	23	\$0.84	\$0.96	-12.3%	-\$0.12	Utilization
8	BLOOD MODIFYING	43	\$0.17	\$0.28	-37.5%	-\$0.10	Discount
9	CHILD BIRTH	65	\$0.01	\$0.11	-92.1%	-\$0.10	Utilization
10	CANCER	13	\$2.08	\$2.17	-4.4%	-\$0.10	Inflation/ Mix



# Trend Components: Increases Specialty

## By Indication

- Majority due to increased Inflation/ Mix

Overall Specialty Trend	
Current Plan Cost PMPM	\$18.75
Previous Plan Cost PMPM	\$14.85
% Change Plan Cost PMPM	26.3%

Total Trend %							
Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (+)
1	MULTIPLE SCLEROSIS	2	\$5.83	\$2.94	98.3%	\$2.89	Utilization
2	HEPATITIS	4	\$1.40		0.0%	\$1.40	Newly Utilized
3	SKIN CONDITIONS	6	\$0.70		0.0%	\$0.70	Newly Utilized
4	INFLAMMATORY CONDITIONS	1	\$6.27	\$5.75	9.1%	\$0.52	Inflation/ Mix
5	PAIN/INFLAMMATION	8	\$0.34		0.0%	\$0.34	Newly Utilized
6	BONE CONDITIONS	9	\$0.23	\$0.19	23.7%	\$0.04	Inflation/ Mix
7	RESPIRATORY CONDITIONS	7	\$0.38	\$0.35	9.5%	\$0.03	Inflation/ Mix
8	INFERTILITY	5	\$1.22	\$1.21	1.2%	\$0.01	Inflation/ Mix
9	NEUROMUSCULAR CONDITIONS/COSMETIC	13	\$0.01		0.0%	\$0.01	Newly Utilized



# Trend Components: Decreases Specialty

## By Indication

- Decreases in trend vary by specialty drug class and may be due to a number of factors, including a change in demographics, new dispensing guidelines or changes in benefit design

Overall Specialty Trend	
Current Plan Cost PMPM	\$18.75
Previous Plan Cost PMPM	\$14.85
% Change Plan Cost PMPM	26.3%

Total Trend %							
Trend Driver Rank	Indication	Curr Plan Cost Rank	Curr Plan Cost PMPM	Prev Plan Cost PMPM	Plan Cost PMPM % Change	Plan Cost PMPM \$ Change	Primary Trend Driver (-)
1	ANTICOAGULANT	12	\$0.17	\$0.76	-78.0%	-\$0.59	Utilization
2	ASTHMA	11	\$0.22	\$0.47	-53.2%	-\$0.25	Utilization
3	CANCER	3	\$1.76	\$2.00	-12.0%	-\$0.24	Utilization
4	ENDOCRINE DISORDERS	10	\$0.22	\$0.38	-41.7%	-\$0.16	Utilization



**EXPRESS SCRIPTS®**

# Top 25 Drugs

- Represent 44.9% of your total Plan Cost and comprise 16 indications
- 7 of your top 25 are specialty drugs

Top Drugs by Plan Cost										1-13 - 12-13				% Change
										1-14 - 12-14				
AUM Mgmt. Strategy	Rank	Peer Rank	Brand Name	Indication	Rxs	Pts.	Plan Cost	Plan Cost / PMPM	Rank	Rxs	Pts.	Plan Cost / PMPM	Plan Cost / PMPM	
ST/PA	1	2	HUMIRA	INFLAMMATORY CONDITIONS	60	15	\$458,648	\$4.92	1	52	16	\$4.21	17.1%	
N/A	2	10	DULOXETINE HCL	DEPRESSION	480	113	\$206,713	\$2.22	195	10	9	\$0.06	3398.1%	
ST/PA	3	6	SOVALDI	HEPATITIS	6	1	\$173,206	\$1.86						
ST/PA	4	9	COPAXONE	MULTIPLE SCLEROSIS	12	5	\$156,011	\$1.67	4	15	4	\$1.77	-5.4%	
ST/PA	5	4	ENBREL	INFLAMMATORY CONDITIONS	20	7	\$148,531	\$1.59	7	20	7	\$1.51	5.6%	
ST	6	3	NEXIUM	HEARTBURN/ULCER DISEASE	283	92	\$148,201	\$1.59	3	384	122	\$1.99	-19.9%	
ST/PA	7	35	REBIF	MULTIPLE SCLEROSIS	9	3	\$139,598	\$1.50	6	13	4	\$1.70	-11.9%	
N/A	8	7	ABILIFY	MENTAL/NEURO DISORDERS	132	37	\$134,666	\$1.45	5	158	41	\$1.71	-15.5%	
N/A	9	8	HUMALOG	DIABETES	178	54	\$131,379	\$1.41	13	110	36	\$0.70	101.1%	
N/A	10	48	SOLODYN	INFECTIONS	87	27	\$96,414	\$1.03	12	85	31	\$0.82	26.7%	
ST	11	5	CRESTOR	HIGH BLOOD CHOLESTEROL	308	94	\$93,257	\$1.00	8	377	121	\$1.18	-15.2%	
N/A	12	11	LANTUS SOLOSTAR	DIABETES	132	43	\$84,163	\$0.90	15	147	51	\$0.66	37.9%	
PA	13	19	GLEEVEC	CANCER	4	1	\$84,092	\$0.90						
PA	14	20	DEXTRAMPHETAMINE-AMPHET ER	ATTENTION DISORDERS	527	86	\$81,146	\$0.87	9	620	88	\$1.11	-21.9%	
PA	15	34	CIALIS	IMPOTENCE	168	69	\$80,571	\$0.86	22	171	71	\$0.56	55.0%	
N/A	16	23	ATRIPLA	VIRAL INFECTIONS	24	4	\$77,897	\$0.84	24	19	4	\$0.55	51.6%	
ST/PA	17	21	VYVANSE	ATTENTION DISORDERS	432	73	\$77,661	\$0.83	18	362	59	\$0.61	36.9%	
VARIOUS	18	1	COMPOUND	MISC CONDITIONS	198	122	\$67,412	\$0.72	26	232	125	\$0.42	71.8%	
PA	19	30	VIAGRA	IMPOTENCE	134	55	\$65,041	\$0.70	14	144	65	\$0.69	0.8%	
PA/DQM	20	14	SYMBICORT	ASTHMA	201	88	\$64,662	\$0.69	63	69	33	\$0.23	197.8%	
PA	21	27	METHYLPHENIDATE ER	ATTENTION DISORDERS	394	70	\$63,621	\$0.68	11	429	73	\$0.82	-16.9%	
ST	22	15	CELEBREX	PAIN/INFLAMMATION	145	57	\$62,195	\$0.67	17	150	51	\$0.61	9.6%	
ST/PA	23	150	REBIF REBIDOSE	MULTIPLE SCLEROSIS	4	1	\$62,163	\$0.67	97	1	1	\$0.15	337.1%	
N/A	24	31	LANTUS	DIABETES	71	27	\$52,458	\$0.56	27	88	24	\$0.42	34.7%	
ST	25	13	JANUVIA	DIABETES	108	32	\$51,955	\$0.56	36	71	21	\$0.35	57.7%	
				Total Top 25:	4,117		\$2,861,660	\$0.72		3,727		\$22.84	34.5%	
				Differences Between Periods:	390		\$727,412	\$7.88						

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment



# Top 25 Specialty Drugs

- Represent 25.6% of your total Plan Cost and comprise 14 indications

Top Specialty Drugs by Plan Cost													1-13 - 12-13			% Change	
AUM Mgmt. Strategy	Overall Rank	Overall Peer Rank	Indication	Brand Name	1-14 - 12-14			Plan Cost / Rx			Plan Cost PMPM	Overall Rank	Rxs	Pts.	Plan Cost / Rx	Plan Cost PMPM	% Change
					Rxs	Pts.	Plan Cost	Plan Cost / Rx	Plan Cost PMPM								
ST/PA	1	2	INFLAMMATORY CONDITIONS	HUMIRA	60	15	\$458,648	\$7,644	\$4.92	1	52	16	\$7,558	\$4.21	17.1%		
ST/PA	3	6	HEPATITIS	SOVALDI	6	1	\$173,206	\$28,868	\$1.86								
ST/PA	4	9	MULTIPLE SCLEROSIS	COPAXONE	12	5	\$156,011	\$13,001	\$1.67	4	15	4	\$11,027	\$1.77	-5.4%		
ST/PA	5	4	INFLAMMATORY CONDITIONS	ENBREL	20	7	\$148,531	\$7,427	\$1.59	7	20	7	\$7,058	\$1.51	5.6%		
ST/PA	7	35	MULTIPLE SCLEROSIS	REBIF	9	3	\$139,598	\$15,511	\$1.50	6	13	4	\$12,228	\$1.70	-11.9%		
PA	13	19	CANCER	GLEEVEC	4	1	\$84,092	\$21,023	\$0.90								
ST/PA	23	150	MULTIPLE SCLEROSIS	REBIF REBIDOSE	4	1	\$62,163	\$15,541	\$0.67	97	1	1	\$14,268	\$0.15	337.1%		
N/A	29	53	INFERTILITY	GONAL-F RFF REDJECT	14	9	\$43,370	\$3,098	\$0.47								
PA	37	50	CNS/AUTONOMIC DISORDERS	H.P. ACTHAR	1	1	\$33,092	\$33,092	\$0.36								
PA	41	144	CANCER	TARCEVA	5	1	\$31,712	\$6,342	\$0.34	32	6	1	\$5,867	\$0.38	-9.6%		
N/A	44	42	ANTICOAGULANT	ENOXAPARIN SODIUM	22	15	\$30,602	\$1,391	\$0.33	52	28	18	\$854	\$0.26	28.4%		
PA	49	46	ASTHMA	XOLAIR	7	2	\$29,268	\$4,181	\$0.31	19	13	2	\$4,317	\$0.60	-47.7%		
PA	51	276	ENDOCRINE DISORDERS	SENSIPAR	8	2	\$27,328	\$3,416	\$0.29	57	8	3	\$2,807	\$0.24	22.1%		
ST/PA	53	113	INFLAMMATORY CONDITIONS	SIMPONI	3	1	\$25,749	\$8,583	\$0.28	41	4	1	\$7,669	\$0.33	-15.8%		
N/A	54	422	INFECTIONS	TOBRAMYCIN	2	2	\$25,406	\$12,703	\$0.27								
N/A	57	103	RESPIRATORY CONDITIONS	PULMOZYME	3	1	\$24,356	\$8,119	\$0.26	58	3	1	\$7,442	\$0.24	9.4%		
N/A	61	274	CANCER	XELODA	11	1	\$22,834	\$2,076	\$0.25	90	4	1	\$3,747	\$0.16	52.8%		
PA	63	173	MULTIPLE SCLEROSIS	AMPYRA	5	2	\$21,402	\$4,280	\$0.23	74	7	1	\$2,732	\$0.20	12.3%		
ST/PA	66	654	BLOOD CELL DEFICIENCY	ARANESP	4	1	\$20,915	\$5,229	\$0.22	82	5	1	\$3,323	\$0.18	26.3%		
ST/PA	77	40	SKIN CONDITIONS	STELARA	1	1	\$16,092	\$16,092	\$0.17								
N/A	80	1274	INFECTIONS	TOBI	2	1	\$14,669	\$7,334	\$0.16								
ST/PA	86	38	MULTIPLE SCLEROSIS	AVONEX PEN	1	1	\$14,017	\$14,017	\$0.15								
N/A	111	675	ANTICOAGULANT	FRAGMIN	4	1	\$11,096	\$2,774	\$0.12								
ST/PA	142	64	GROWTH DEFICIENCY	NORDITROPIN FLEXPRO	4	1	\$8,225	\$2,056	\$0.09	718	3	1	\$100	\$0.00	2650.5%		
N/A	146	134	INFERTILITY	MENOPUR	8	4	\$7,889	\$986	\$0.08	303	3	2	\$1,076	\$0.03	145.2%		
			Total Top 25:		220		\$1,630,269	\$7,410	\$17.50		185		\$6,042	\$11.96	46.3%		
			Difference Between Periods:		35		\$512,528	\$1,368	\$5.54								

Peer = Express Scripts Peer 'Midmarket Employer - Elementary & Secondary Schools' market segment



Confidential and Proprietary Information  
© 2015 Express Scripts Holding Company. All Rights Reserved.

